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 23 
Abstract  24 
Disorders such as depression and anxiety exhibit strong sex differences in their 25 
prevalence and incidence, with women also differing from men in their response to 26 
antidepressants. Furthermore, receptors for corticotrophin releasing hormone 27 
(CRHR1) and arginine vasopressin (AVPR1b) are known to contribute to the 28 
regulation of mood and anxiety. In the present study, we compared the anxiety profile 29 
and CRHR1 and AVPR1b expression levels in control Sprague Dawley (SD) rats and 30 
rats of the SD-derived Flinders Sensitive Line (FSL), a genetic model of depression. 31 
Additionally, given the apparent sex differences in the therapeutic efficacy of 32 
antidepressants and because antidepressants are commonly used to treat comorbid 33 
anxiety and depressive symptoms, we assessed whether the anxiolytic effects of an 34 
antidepressant occur in a sex-dependent manner. Male and female FSL rats were 35 
treated with citalopram 10mg/kg once daily for 14 days and were then tested in the 36 
open field and the elevated plus maze paradigms. Upon completion of the 37 
behavioural analysis, AVPR1b and CRHR1 expression levels were monitored in the 38 
hypothalamus and the prefrontal cortex (PFC) using western blotting. According to 39 
our results, male FSL rats were more anxious than control SD rats, a difference 40 
abolished by citalopram treatment. Baseline anxiety levels were similar in female FSL 41 
and SD rats, and citalopram further reduced anxiety in female FSL rats. Importantly, 42 
whereas citalopram altered AVPR1b expression in the hypothalamus of male FSL 43 
rats, its actions on this parameter were restricted to the PFC in female FSL rats. In 44 
both sexes of FSL rats, citalopram did not alter CRHR1 expression in either the 45 
hypothalamus or PFC. Our results demonstrate that antidepressant treatment 46 
reduces anxiety levels in FSL rats of both sexes: the magnitude of treatment effect 47 
was related to the starting baseline level of anxiety and the antidepressant elicited 48 
sexually differentiated neurobiological responses in specific brain regions. 49 
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 69 
Article Highlights 70 
 Male, but not female, Flinders Sensitive Line of rats present anxiety behaviour 71 
 Repeated citalopram treatment reduces anxiety levels in both sexes 72 
 Citalopram modulates AVPR1b expression in a sex-specific manner 73 
 Differing mechanisms converge to produce anxiolysis in FSL rats of both 74 
sexes 75 
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1. Introduction 77 
Stress and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis are 78 
implicated in the pathophysiology of mood and anxiety disorders (Tsigos and 79 
Chrousos, 2002), which show greater comorbidity and prevalence in women (Kessler 80 
et al., 1994, Alonso et al., 2004). Two hypothalamic drivers of the HPA axis, 81 
corticotropin releasing hormone (CRH) and arginine vasopressin (AVP), also 82 
influence mood and emotional behaviour through their actions at extra-hypothalamic 83 
sites (Holsboer and Ising, 2008). The actions of CRH are mediated by two receptor 84 
subtypes (Lowry and Moore, 2006). The CRH subtype 1 receptor (CRHR1) 85 
modulates context-dependent affective responses and is expressed in the 86 
hypothalamus and extra-hypothalamic areas, including the frontal cortex (Sanchez et 87 
al., 1999). On the other hand, cerebral vasopressin pathways show distinct 88 
anatomical and functional patterns (Ermisch et al., 1993); most central actions of this 89 
peptide are mediated by subtype 1b vasopressin receptors (AVPR1b) which are also 90 
expressed in the hypothalamus and frontal cortex (Hernando et al., 2001). 91 
Increasingly, AVPR1b are being implicated in behaviours relevant to mood and 92 
anxiety disorders (Surget and Belzung, 2008). Antagonism of either CRHR1 or 93 
AVPR1b results in anxiolytic and antidepressant effects, suggesting these receptors 94 
as alternatives to the current monoaminergic drug targets (Surget and Belzung, 95 
2008, Binder and Nemeroff, 2010). 96 
Sex differences in the activity of the HPA axis are well known and the sexually 97 
differentiated response to stress is increasingly thought to be an important underlying 98 
factor in mood and anxiety disorders (Young, 1998, Goel and Bale, 2009, Young and 99 
Korszun, 2010). Women are nearly twice as likely to suffer from depression (Kessler 100 
et al., 1994, Alonso et al., 2004). Moreover, as compared to men, depressed women 101 
make a greater number of suicide attempts, show more somatisation, anger and 102 
hostility, and display increased appetite and weight gain. Importantly, although 103 
melancholic depression occurs equally in both sexes, the anxious and atypical forms 104 
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of depression are more commonly found in women (Frank et al., 1988, Marcus et al., 105 
2005, Marcus et al., 2008), although the construct of anxious depression has 106 
received some criticism (Nelson, 2008). It is now well-established that estrogens 107 
influence depressive symptoms, including irritability, insomnia, appetite, and general 108 
physical well-being (Young et al., 2007, Kornstein et al., 2010). Together, these 109 
observations suggest the potential importance of considering the role of sex and the 110 
ovarian steroid milieu in measuring the efficacy of antidepressant therapy. Indeed, 111 
several studies have reported that women respond better to selective serotonin re-112 
uptake inhibitors (SSRI) (Kornstein et al., 2000, Joyce et al., 2003, Baca et al., 2004, 113 
Khan et al., 2005); a similar conclusion was reached in a recent large multicentre trial 114 
of citalopram (Marcus et al., 2008). Nevertheless, some authors have argued that 115 
sex differences in response to antidepressant treatment may be clinically irrelevant 116 
(Quitkin et al., 2002, Hildebrandt et al., 2003, Parker et al., 2003, Wohlfarth et al., 117 
2004, Thiels et al., 2005). 118 
Experimental studies from our group and others have consistently demonstrated 119 
increased female vulnerability to the detrimental effects of stress on mood- and 120 
anxiety-related behaviours (Patchev and Almeida, 1998, Dalla et al., 2010, 121 
Pitychoutis and Papadopoulou-Daifoti, 2010, Pitychoutis et al., 2010). Furthermore, 122 
our previous studies showed that antidepressants elicit similar, albeit differing in 123 
magnitude, behavioural responses in male and female rats of the Flinders Sensitive 124 
Line (FSL); serotonergic and glutamatergic responses also differ between the two 125 
sexes following antidepressant treatment (Kokras et al., 2009a, Kokras et al., 2009b). 126 
FSL rats, derived by selective breeding of Sprague-Dawley (SD) rats, have several 127 
key characteristics which support the face, construct and predictive validity of this 128 
model of depression (Overstreet, 2002). FSL rats exhibit decreased weight and 129 
disturbed appetite, have elevated REM sleep, present anhedonia in chronic mild 130 
stress and are less active in novel environments; at the same time they are inherently 131 
more immobile in the forced swim test. Furthermore, in brain limbic areas, FSL rats 132 
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show significant regional abnormalities in levels of biogenic amines and their 133 
receptors, reduced serotonin synthesis, impaired serotonin-induced dopamine 134 
release, and impairments in their immune system (Overstreet et al., 2005). 135 
Importantly, chronic and not acute treatment with antidepressants restores those 136 
observed behavioural and neurobiological abnormalities (Yadid et al., 2000). 137 
Despite the large body of evidence supporting the validity of the FSL model of 138 
depression, it still remains unclear whether FSL rats can model comorbid anxious 139 
depression. Previous research on male FSL showed increased levels of anxiety in 140 
the social interaction test (Overstreet, 2002, Janowsky et al., 2004, Lavi-Avnon et al., 141 
2005) but not in the elevated plus maze (EPM) (Schiller et al., 1991, Overstreet et al., 142 
1995). Whereas male FSL rats have been well studied, relatively fewer studies have 143 
focused on female FSL animals. While our previous studies confirmed the validity of 144 
female FSL rats as a model of depression (Kokras et al., 2009a, Kokras et al., 145 
2009b), there is no information with respect to their anxiety profile and expression 146 
levels of CRHR1 and AVPR1b. 147 
Based on the aforementioned sex-differences and the documented validity of 148 
male and female FSL rats as a model of depression, a first aim of the present study 149 
was to explore the potential suitability of the FSL rat as a model of comorbid anxious 150 
depression. Further, given that male FSL rats were previously reported to be 151 
sensitive to the behavioural actions of CRHR1 and AVPR1b antagonists (Janowsky 152 
et al., 2004, Overstreet et al., 2004, Overstreet et al., 2005) we examined the 153 
expression of brain CRHR1 and AVPR1b in male and female FSL rats under 154 
baseline conditions and after repeated citalopram treatment. 155 
 156 
2. Experimental Procedures 157 
 158 
2.1 Animals 159 
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Twenty-four adult male and female FSL rats, weighing 275±17 g and 200±15 160 
g, respectively, and aged 10-11 weeks at the beginning of the experiment, were 161 
used. In addition, 24 male and female, similarly aged, Sprague-Dawley rats, weighing 162 
325±26 g and 245±20 g respectively, were used as controls as previously described 163 
(Overstreet et al., 2005). Animals were group-housed, according to sex, under 164 
controlled 12:12 light/dark cycles (lights on at 07:00 a.m.) and temperature (222 °C), 165 
with free access to food and tap water. All animal experiments were carried out in 166 
accordance with the EEC directive 86/609. 167 
 168 
2.2 Oestrous Cycle 169 
In the case of females, a semi-random process controlled for disparities 170 
regarding the phases of the oestrous cycle. Specifically, female rats were selected 171 
from a larger pool of experimental animals on the basis of a normal 4-5 day cycle and 172 
assigned to groups on the basis of an equal distribution of oestrous cycle phases; the 173 
latter was monitored by vaginal smears until the day of sacrifice, as described 174 
elsewhere (Becker et al., 2005). Oestrous cycle phases on the day of behavioural 175 
testing and sacrifice are reported in Table 1. 176 
 177 
2.3 Treatments 178 
FSL and control SD rats were gently handled, daily by the same researcher. 179 
Male and female animals were given intra-peritoneal injections of either saline (FSL 180 
n=12; SD n=12) or 10mg/Kg of citalopram (Lundbeck S.A., Denmark; FSL n=12; SD 181 
n=12) during the morning, over 14 days. This dose of citalopram was previously 182 
shown to be effective and has been routinely used in male and female rats 183 
(Burghardt et al., 2004, Overstreet et al., 2004, Hasegawa et al., 2005).  184 
 185 
2.4 Open Field 186 
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Spontaneous activity under novelty stress was measured for 5 min, 187 
approximately 22-26 h after the last injection of saline or citalopram (day 15). As 188 
previously described (Pitychoutis et al., 2009b), all rats were acclimatized to the test 189 
room for 1 h and thereafter placed in a clear Plexiglas chamber (Med Associates Inc., 190 
St Albans, VT) measuring 430 x 430 x 300 mm with arrays of 16 x 16 photodetectors, 191 
positioned 2.5 cm and 10 cm above the floor of the chamber. Interruption of adjacent 192 
photobeams provided an index of ambulatory activity (horizontal activity) while 193 
interruption of the upper line of photobeams provided an index of rearing behaviour 194 
(vertical activity). The time spent at the centre of the chamber served as an index of 195 
anxiety (Belzung and Griebel, 2001). 196 
 197 
2.5 Elevated Plus Maze 198 
The Elevated Plus Maze (EPM) test was conducted under dim light, 199 
approximately 1 min after the open field test. The test sequence from the open field 200 
to the elevated plus maze is known to enhance exploratory activity and to improve 201 
the reliability of plus-maze testing (Pellow et al., 1985). Each rat was placed facing 202 
an open-arm in the middle of the EPM, which was placed 50 cm above the ground 203 
and consisted of two open (50 x 10 cm) and two identical arms, enclosed within 50 204 
cm high walls with a symmetrical 100 cm2 square area at the centre. The number of 205 
total and open arm entries was recorded for 5 minutes. An index of anxiety was 206 
obtained from the ratio of the time spent in the open arms vs. the total time in the 207 
maze (Doremus et al., 2006). Upon completion of the behavioural testing, rats were 208 
returned to their home cages. 209 
 210 
2.6 Western blot analysis 211 
Twenty minutes after behavioural analysis, all animals were rapidly sacrificed 212 
and the prefrontal cortex and the hypothalamus were dissected out, snap-frozen in 213 
liquid nitrogen and stored at –80° C. Their brains were rapidly removed and for the 214 
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dissection of the regions of interest a method described in detail by (Heffner et al., 215 
1980) was followed with minor modifications, as described in (Kokras et al., 2009b). 216 
In short, two sagittal sections, rostrally to caudally, separated the prefrontal cortex 217 
from the frontal lobe and the rest of the brain. Samples were homogenized using a 218 
Dounce glass homogenizer in lysis buffer containing 100 mM Tris-HCl, 250 mM 219 
NaCl, 1 mM EDTA, 5 mM MgCl2, 1% NP-40, Complete Protease Inhibitor (Roche, 220 
Mannheim, Germany) and Phosphatase Inhibitor Cocktails I and II (Sigma, St. Louis, 221 
MO). Extracts were cleared by centrifugation (14000 g) and protein contents were 222 
estimated by Lowry assay. Protein lysates (40ug) were electrophoresed on 10% 223 
acrylamide gels in Laemmli buffer (250 mm Tris-HCl, pH 6.8, containing 4% SDS, 224 
10% glycerol, 2% β-mercaptoethanol, and 0.002% bromophenol blue) and 225 
transferred onto nitrocellulose membranes (Protran BA 85, Schleicher & Schuell, 226 
Dassel, Germany). The membranes were blocked in TBS containing 5% non-fat milk 227 
and 0.2% Tween-20 before incubation with anti-AVPR1b (1:1000; AB3510P, 228 
Chemicon, Temecula, CA) and anti-CRHR1 kindly provided by Dr. E.A. Linton 229 
(1:200; Oxford), described in (Castro et al., 1996). For normalization purposes, blots 230 
were also probed with anti--actin (1:2000; Chemicon). Following incubation with 231 
horseradish peroxidase–IgG conjugates (Amersham Biosciences, Freiburg, 232 
Germany), antigens were revealed by enhanced chemiluminescence (ECL, 233 
Amersham Biosciences). Band intensities were evaluated by densitometry and all 234 
values were normalized and expressed as percentages of control male vehicle – 235 
treated SD rats. 236 
 237 
2.7 Corticosterone assay 238 
Trunk blood samples were collected at sacrifice and processed to recover 239 
serum (centrifugation at 4000 g, 30 min, 4°C); serum samples were stored at -20° C 240 
before being assayed for corticosterone by a standard radioimmunoassay (MP 241 
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Biomedicals, Costa Mesa, CA). The inter- and intra-assay coefficients of variation 242 
were both 8%. 243 
 244 
2.8 Statistical Analysis 245 
All results presented herein were analyzed with three-way ANCOVA using the 246 
General Linear Model of SPSS version 19 (IBM Corp, Somers, NY, USA) with “strain” 247 
(FSL vs. control SD), “sex” (male vs. female) and “drug” (citalopram vs. vehicle) as 248 
independent variables. Subsequent one-way ANCOVAs were performed to elucidate 249 
significant results as indicated by the factorial model. Specifically for corticosterone, 250 
pearson’s correlations with behavioural outcomes were calculated. Oestrous cycle 251 
phase was used as a covariate in all factorial analysis to control variance due to the 252 
female hormonal milieu and to increase the validity of the male/female comparison. 253 
In this study, the main effect of oestrous cycle was not significant in any of the 254 
statistical analyses described further on; however this study was not designed to 255 
specifically detect oestrous cycle effects but merely to control for them. A probability 256 
value of p≤0.05 was considered as significant. 257 
 258 
3. Results 259 
 260 
3.1 Behavioural measurements 261 
 262 
3.1.1 Open Field test 263 
 264 
Horizontal activity. Statistical analysis indicated a significant “sex” main 265 
effect, as female FSL and SD rats generally showed higher ambulatory counts than 266 
their strain-matched male controls [F(1,39)=27.553 p<0.001]. Furthermore, a significant 267 
“strain” main effect was observed [F(1,39)=9.259 p=0.004], reflecting the lower 268 
ambulatory counts of FSL rats during the 5 min open field test. Male FSL rats 269 
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displayed considerable lower horizontal activity than their SD counterparts 270 
[F(1,10)=46,507 p<0.001] (Figure 1a). 271 
 272 
Vertical Activity. Statistical analysis revealed a significant “sex” main effect 273 
[F(1,39)=38.263 p<0.001], as female SD and FSL rats generally had higher vertical 274 
counts than males of the corresponding strains (Figure 1b). 275 
 276 
Time in centre. The factorial model revealed significant “strain x sex” and 277 
“strain x drug” interactions [F(1,39)=8.344 p=0.006; F(1,39)=10.429 p=0.003]. Further 278 
analysis showed that male, but not female, FSL rats spent less time in the centre of 279 
the arena than their sex-matched SD counterparts [F(1,10)=5.171 p=0.046]. 280 
Citalopram-treated male FSL rats displayed considerably more time in the centre of 281 
the arena than vehicle-treated male FSL rats [F(1,10)=27.128 p<0.001]. Interestingly, 282 
citalopram-treated female FSL rats also showed a significant increase in the time 283 
spent in the centre of the arena [F(1,9)=8.749 p=0.016] (Figure 1c). 284 
 285 
3.1.2 Elevated Plus Maze test 286 
 287 
Total arm entries. Statistical analysis revealed a significant “sex” main effect 288 
[F(1,39)=4.288 p=0.045], indicating that female SD and FSL rats made more arm 289 
entries than SD and FSL males, respectively (Figure 2a). 290 
 291 
Open arm entries. Regarding open arm entries, a significant “sex” main 292 
effect [F(1,39)=6.443 p=0.015] was found, indicating that female SD and FSL rats 293 
make more open arm entries than their male counterparts (Figure 2b). 294 
 295 
Time in open arms. Statistical analysis uncovered significant “strain x sex” 296 
and “strain x drug” interactions on this parameter [F(1,39)=8.305 p=0.006; 297 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
12 
 
F(1,39)=15.002 p<0.001 respectively]. As compared to respective SD controls, male, 298 
but not female, FSL rats spent less time in the open arms of the apparatus 299 
[F(1,10)=126.772 p<0.001]. However, citalopram treatment elongated the time spent in 300 
the open arms in FSL rats of both sexes [males: F(1,10)=24.874 p=0.001; females: 301 
F(1,9)=5.666 p=0.041] (Figure 2c). 302 
 303 
3.3 Neurobiological measurements 304 
 305 
3.3.1 Corticosterone Serum Levels 306 
Statistical analysis revealed that female FSL and SD rats had significantly 307 
higher corticosterone serum levels [F(1,39)=20.314 p<0.001]. Furthermore, male FSL 308 
rats had significantly higher corticosterone levels than control male SD rats 309 
[F(1,10)=35,426 p<0.001]. Citalopram treatment mediated a significant decrease in 310 
corticosterone levels in male FSL rats as compared to vehicle treated male FSL rats 311 
[F(1,10)=17.380 p=0.002]. However, citalopram treatment had no effect in female FSL 312 
rats (Figure 3a). Furthermore, Pearson’s correlation analysis showed that 313 
corticosterone levels significantly and inversely correlated in males only with the time 314 
spent in the centre of the open field and in the open arms of the EPM [r(24)= -0.590, 315 
p=0.002; r(24)= -656, p<0.001 respectively], as shown in the scatter plot (figure 3b). 316 
These correlations were not significant for female rats. Similarly, a linear regression 317 
model for corticosterone with behavioural and neurobiological measurements as 318 
predictors did not produce significant results. 319 
 320 
3.3.2. CRHR1 expression levels 321 
Immunoblotting was used to monitor CRHR1 levels in the hypothalamus and 322 
PFC. Regarding hypothalamic CRHR1, the analysis revealed a significant “strain” 323 
main effect; male and female FSL rats were found to have significantly lower levels of 324 
CRHR1 expression than SD rats [F(1,39)=11.478 p=0.002] (Figure 4a). Citalopram 325 
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exhibited no effect on CRHR1 levels. A similar analysis of CRHR1 expression in the 326 
PFC indicated a significant “strain x drug” interaction [F(1,39)=6.617 p=0.014] (Figure 327 
4b). Further analysis showed that, similar to observations in the hypothalamus, the 328 
prefrontal cortex of male and female FSL rats exhibits lower levels of CRHR1 than 329 
their SD counterparts [F(1,39)=50.330 p<0.001]. Notably, citalopram treatment resulted 330 
in differential effects in the two rat lines: while the antidepressant failed to produce 331 
any effect in male and female FSL rats, it increased CRHR1 expression in male and 332 
female SD rats [F(1,10)=7.024 p=0.024; F(1,9)=5.565 p=0.043] (Figure 4b).  333 
 334 
3.3.3. AVPR1b expression levels 335 
The statistical analysis for AVPR1b hypothalamic expression levels indicated 336 
a significant “strain x sex x drug interaction” [F(1,39)=9.067 p=0.005] (Figure 4c). 337 
Vehicle-treated male, but not female, FSL rats showed higher hypothalamic AVPR1b 338 
expression levels than their SD counterparts [F(1,10)=24.238 p=0.001]. Further 339 
analysis revealed that citalopram lowered hypothalamic AVPR1b expression levels in 340 
male [F(1,10)=8.762 p=0.014], but not female, FSL rats (Figure 4c). Regarding cortical 341 
AVPR1b expression levels, the analysis showed a significant “sex x drug” interaction 342 
[F(1,39)=7.163 p=0.011]. Further analysis showed that female FSL rats had lower 343 
cortical AVPR1b than the sex-matched SD rats [F(1,9)=11.440 p=0.008]. Finally, 344 
whereas citalopram did not have a significant effect in males, it robustly increased 345 
cortical AVPR1b in female FSL rats [F(1,9)=5.674 p=0.041] (figure 4d). 346 
 347 
4. Discussion 348 
Although depression and anxiety have greater prevalence and different 349 
phenomenology in women, the biological mechanisms underlying such sex 350 
differences are not well understood. Likewise, reports on the sex-differentiated 351 
antidepressant response remain controversial. The present study used a well-352 
validated model of depression and explored its suitability as a model of comorbid 353 
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anxious depression, taking into consideration sex-differences in anxiety and 354 
depression at baseline and following treatment. In addition, this study explored 355 
possible links between anxiety-like behaviour, corticosterone levels and the 356 
expression of CRHR1 and AVPR1b in FSL animals under baseline conditions and 357 
post-antidepressant treatment. 358 
Our results showed that male, but not female, FSL rats are less active and 359 
show greater signs of anxiety than their sex-matched SD controls. These findings are 360 
in agreement with the previously reported anxious profile of male FSL rats in the 361 
social interaction test (Overstreet, 2002, Janowsky et al., 2004, Lavi-Avnon et al., 362 
2005). Differences between the present EPM results and those reported previously 363 
(Schiller et al., 1991, Overstreet et al., 1995) may be explained by methodological 364 
differences. In fact, male FSL rats adopt passive coping strategies when challenged 365 
in behavioural tests (Overstreet, 2002, Overstreet et al., 2005) and the sequential 366 
behavioural testing along with the repeated injections in this study, possibly provoked 367 
the anxiety-like behavioural response of male FSL rats. 368 
In contrast to males, female rats (of both strains) were generally more active, 369 
as reported by others too (Brotto et al., 2000, Romero and Chen, 2004). This is 370 
thought to reflect sex-specific coping strategies and hormonal environment (Palanza, 371 
2001, Dalla et al., 2010); the latter is particularly relevant since gonadal hormones 372 
are known to influence activity in rodents (Nomikos and Spyraki, 1988, Becker et al., 373 
2005) and phenomenology of depression in humans (Kornstein et al., 2010). Rather 374 
than focussing on the contribution of individual gonadal hormones using ablation and 375 
hormone replacement strategies (Becker et al., 2005), the present experiments were 376 
designed to average and control for such potentially confounding effects. Thus, while 377 
we previously confirmed a depressive-like phenotype in female FSL rats (Kokras et 378 
al., 2009a), it was interesting to find here that FSL females do not express anxiety-379 
like behaviour. This finding is in contrast to those reported in humans, given that 380 
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previous research has established that women present more often anxious 381 
depression than men (Frank et al., 1988, Marcus et al., 2005, Marcus et al., 2008). 382 
Based on the aforementioned observations, we conclude that while the FSL 383 
rat is a well-validated genetic model for studying depressive-like behaviour, anxiety in 384 
male FSL rats is dependent on the experimental protocol, hence the previously 385 
conflicting results. In addition, while female rats were not anxious in our study, we 386 
cannot exclude that using other protocols they might also present anxiety. In 387 
summary, our results point towards anxiety being state, rather than trait, dependent 388 
in FSL rats; this limits their potential as a model of anxious depression. Interestingly, 389 
should we have used only male FSL rats in our study, the unexpected sex-390 
differentiated anxious profile of FSL rats, being the polar opposite of the human 391 
condition, would have gone unnoticed. Therefore, in agreement with previous 392 
suggestions (Palanza, 2001, Dalla et al., 2010), our findings highlight the importance 393 
of considering both sexes when studying animal models of disease. 394 
With regards to treatment, whereas citalopram did not influence anxiety levels 395 
in control SD rats, the drug robustly reduced anxiety levels in both sexes of the FSL 396 
model of depression. The anxiolytic or anxiogenic effect of different SSRI treatments 397 
on male rats has been previously reviewed thoroughly (Borsini et al., 2002) and in 398 
our study, the behaviour of control SD rats was unaffected by this particular dose of 399 
repeated SSRI treatment when rats were tested after a 24 hours wash-out period, in 400 
agreement with similar studies (Wikell et al., 1999). However, behavioural effects 401 
have also been reported under different antidepressant doses and experimental 402 
protocols (Kugelberg et al., 2002, Mombereau et al., 2010). It is worth noting that in 403 
FSL rats repeated citalopram treatment did not alter locomotor/exploratory 404 
behavioural indices but selectively affected anxiety-related behavioural responses. 405 
Interestingly, the drug-induced responses of male and female FSL rats differed in 406 
magnitude, reflecting their different baseline levels of anxiety. In light of our earlier 407 
studies (Drossopoulou et al., 2004, Dalla et al., 2005, Dalla et al., 2008, Kokras et al., 408 
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2009a, Kokras et al., 2009b, Pitychoutis et al., 2009a), we conclude that baseline 409 
levels of anxiety in males and females of this model of depression result from sex-410 
differentiated strategies to cope with identical behavioural challenges. Most 411 
interestingly, repeated antidepressant treatment masks such differences and 412 
produces a converging behavioural response. 413 
This conclusion receives further support given that we only found a significant 414 
correlation between corticosterone levels and anxiety in males, although both sexes 415 
displayed reduced anxiety levels after repeated treatment with citalopram. The higher 416 
corticosterone levels found in male FSL rats most likely reflect their susceptibility to 417 
distress during handling and subsequent behavioural testing, possibly related to their 418 
impaired serotoninergic transmission (Yadid et al., 2000). Reversal of the latter by 419 
repeated antidepressant treatment attenuates stress-induced drive on the HPA axis, 420 
corticosterone and anxiety levels. On the other hand, female rats had higher 421 
corticosterone levels, as consistently reported (Dalla et al., 2010). Curiously, while 422 
female FSL also have an impaired serotoninergic system (Kokras et al., 2009a), and 423 
despite the SSRI-induced behavioural effect, treatment did not attenuate their 424 
baseline corticosterone levels. Similar sex differences in the contribution of the HPA 425 
axis to antidepressant actions have been reported (Binder et al., 2009, Horstmann et 426 
al., 2009, McEuen et al., 2009, Goel and Bale, 2010), suggesting that in female FSL 427 
(and perhaps more generally in females), additional mechanisms may influence the 428 
HPA axis, thus obscuring the correlation of corticosterone levels with behavioural 429 
outcomes following treatment. 430 
It is known that sex differences in the regulation of corticosteroid secretion, 431 
synthesis and release of hypothalamic CRH and AVP arise during sexual 432 
organization of the brain early in life; on the other hand, the regulation of these 433 
hormones remains subject to the influence of fluctuations in gonadal secretory 434 
activity throughout life (Patchev et al., 1999). Importantly, central CRH and AVP 435 
receptors are implicated in mood and anxiety disorders and in the response to 436 
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antidepressant treatment. Here, we found that, as compared to SD rats, male and 437 
female FSL rats display lower CRHR1 receptors levels at both hypothalamic and 438 
cortical sites. Since CRHR1 has been implicated in depression in humans and 439 
mouse models (Timpl et al., 1998, Muller et al., 2003), these findings add to the view 440 
that FSL rats are a good model for understanding the neurobiological basis of 441 
depression. Interestingly, CRHR polymorphisms play an important role in the 442 
therapeutic efficacy of citalopram in anxious depression (Binder et al., 2010) and 443 
other studies have suggested interactions between CRHR1, AVPR1b and serotonin 444 
in mediating the actions of established antidepressants (Ishizuka et al., 2010, 445 
Magalhaes et al., 2010). Curiously, the results of the present study show that 446 
citalopram exerts anxiolytic actions in male and female FSL rats without altering 447 
CRHR1 expression levels. Notably, while the results of pharmacological studies in 448 
FSL rats implicate CRHR1 in the expression of depressive-like behaviour (Overstreet 449 
et al., 2004, Lavi-Avnon et al., 2005), we found here that citalopram induced changes 450 
in CRHR1 levels in SD animals even though these animals did not show behavioural 451 
responses to the drug. Offering an explanation for these apparent anomalies is 452 
difficult but the fact that FSL and SD animals show substantial differences in their 453 
baseline anxiety levels may be an important consideration. Indeed, previous studies 454 
reported that repeated SSRI treatment may affect the temporal co-localization of AVP 455 
and CRH (To et al., 1999, Moncek et al., 2003), initially affecting the CRH 456 
subsystem, and later modifying the AVP subsystem (Keck et al., 2003, Hesketh et 457 
al., 2005). 458 
Indeed, our results show that male FSL rats, which display an anxious phenotype 459 
under baseline conditions, express higher levels of hypothalamic AVPR1b as 460 
compared to SD males. Interestingly, we also show that repeated administration of 461 
citalopram leads to a downregulation of hypothalamic AVPR1b and, in parallel, 462 
reduced corticosterone and anxiety-like behaviour in male FSL rats. In contrast, 463 
female FSL rats (non-anxious phenotype under basal conditions) exhibit lower 464 
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cortical AVPR1b mRNA levels than female SD rats. This profile was reversed by 465 
repeated citalopram treatment and the drug led to a further reduction of basal anxiety 466 
levels in female FSL rats without affecting corticosterone levels. Although the 467 
underlying mechanisms remain elusive at this time, these findings highlight the fact 468 
that the responses to citalopram are sexually differentiated in FSL animals. Given the 469 
observations that the therapeutic effects of citalopram in males are associated with a 470 
reduction in corticosterone levels, we suggest that the HPA axis plays a critical role in 471 
the regulation of anxiety in males in this sex (see Table 2). Other pathways and 472 
mechanisms appear to underlie the actions of citalopram in females; specifically, our 473 
results suggest that modulation of extra-hypothalamic (cortical) AVPR1b may be 474 
important for the anxiolytic actions of citalopram in female FSL rats (see Table 2). 475 
In summary, our results suggest that although male and female FSL rats are a 476 
good model for research on depression, they are not suitable for accurately 477 
modelling comorbid anxious depression, as observed in humans. Interestingly 478 
though, SSRI treatment triggers distinct neurobiological mechanisms in male and 479 
female rats of this model of depression. These mechanisms result in similarly 480 
converging behavioural response in both sexes, although of different magnitude, 481 
depending on the pre-treatment baseline. It is thus suggested that similar phenotypic 482 
endpoints can arise from divergent neurobiological mechanisms, a concept 483 
previously suggested for central vasopressinergic transmission (De Vries and 484 
Panzica, 2007). It may be further suggested that the neurobiological effects of 485 
antidepressants are not strictly predetermined, but rather depend on the substrate 486 
(e.g. male or female brain, depressive and/or anxious status or not). Thus, our 487 
observations raise the question of whether a patient’s clinical response to an SSRI 488 
likewise depends on sexually differentiated neurobiological mechanisms. 489 
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Tables 759 
 760 
Table 1: Oestrous Cycle. Distribution of the phases of the oestrous cycle in female 761 
FSL and SD rats treated with vehicle and citalopram. 762 
 763 
Table 2: Summary of behavioural and neurobiological changes induced by 764 
citalopram treatment on male and female FSL rats. Repeated citalopram 765 
treatment evoked an anxiolytic behavioural outcome in both male and female FSL 766 
rats but this was accompanied by hypothalamic AVPR1b and corticosterone changes 767 
in male FSL rats whereas only cortical AVPR1b changes were identified in female 768 
FSL rats. 769 
 770 
Figures 771 
 772 
Figure 1: Open Field: spontaneous horizontal (a) and vertical activity (b) expressed 773 
in photobeam counts, and time spent in the centre of the arena (c) expressed as 774 
percent of total time. Note that male but not female FSL spent less time in centre in 775 
comparison to their SD counterparts, whereas both FSL sexes responded to 776 
citalopram treatment by increasing their time spent in the centre of the arena. All data 777 
shown represent mean ± SEM values; the asterisk (*) represents a significant strain 778 
difference and the hash sign (#) represents a significant drug difference. P<0.05, N=6 779 
per group. 780 
 781 
Figure 2: Elevated Plus Maze test: number of total (a) and open (b) arm entries, 782 
and time spent in the open arms (c) expressed as percent of total time. Note that 783 
male but not female FSL rats spent less time in open arms in comparison to their SD 784 
counterparts but both FSL sexes responded to citalopram treatment by increasing 785 
the percentage of time spent in the open arms. All data shown represent mean ± 786 
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SEM values; the asterisk (*) represents a significant strain difference and the hash 787 
sign (#) represents a significant drug difference. P<0.05, N=6 per group. 788 
 789 
Figure 3: Corticosterone Serum Levels 790 
Male but not female FSL rats presented increased corticosterone serum levels and 791 
citalopram treatment successfully abolished this increase in male FSL rats (a). 792 
Increased corticosterone serum levels correlate with lower time in centre and open 793 
arms in males only (b). CORT=Corticosterone, TC=Time in Centre of the Open Field, 794 
TOA=Time in Open Arms of the Elevated Plus Mase. All data shown represent mean 795 
± SEM values .The asterisk (*) represents a significant strain difference and the hash 796 
sign (#) represents a significant drug difference. P<0.05, N=6 per group. 797 
 798 
Figure 4: CRHR1 and AVPR1b expression levels: Hypothalamic (a) and cortical 799 
(b) CRHR1 and hypothalamic (c) and cortical (d) AVPR1b expression levels of male 800 
and female SD and FSL rats measured by western blot analysis. Representative 801 
blots from each brain region are shown above the respective numeric data in the 802 
same order of appearance: M: Males, F: Females, SV: Sprague-Vehicle, SC: 803 
Sprague-Citalopram, FV: Flinder-Vehicle, FC: Flinder-Citalopram. Western blot 804 
numerical data are based on optical density evaluations normalized against actin and 805 
are depicted relative to control values (male vehicle-treated SD rats) as means ± 806 
SEM. An asterisk (*) represents a significant strain difference and a hash sign (#) 807 
represents a significant treatment effect. P<0.05, N=6 per group. 808 
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Table 1
Males FSL Anxiety Corticosterone HYP AVPR1b PFC AVPR1b
Baseline ↑ ↑ ↑ ↔
Antidepressant ↓ ↓ ↓ ↔
Females FSL Anxiety Corticosterone HYP AVPR1b PFC AVPR1b     
Baseline ↔ ↔ ↔ ↓
Antidepressant ↓ ↔ ↔ ↑
Table 2
Article Highlights 
 Male, but not female, Flinders Sensitive Line of rats present anxiety behaviour 
 Repeated citalopram treatment reduces anxiety levels in both sexes 
 Citalopram modulates AVPR1b expression in a sex-specific manner 
 Differing mechanisms converge to produce anxiolysis in FSL rats of both 
sexes 
 
*Highlights
